Management

BRAM BOUT

CEO, Managing Director

Dr. Abraham (Bram) Bout is Chief Executive Officer and Managing Director of Bioceros B.V.. He previously served as Chief Technology Officer at Profibrix BV (Leiden, The Netherlands) from 2007 – 2014. Prior to joining Bioceros in 2007, he was employed by Crucell (from 1993 till March 2007), where he held several management positions with increasing responsibility. His last position at Crucell was Vice President, Protein Production. Bram is co-inventor of the human PER.C6® production platform which is used for the development and manufacturing of vaccines, monoclonal antibodies, therapeutic proteins and gene therapy products. Bram published over 50 scientific articles and is co-inventor on 90 patents about the PER.C6® cell line technology and in the field of recombinant protein production and gene therapy.

Bram holds a PhD in biochemistry (topic: peroxisomal storage disorders ) at the University of Amsterdam.

LOUIS BOON

CSO, Managing Director

Dr. Louis Boon was one of the founders of PanGenetics BV where he was responsible for project management and animal studies. Since the merger between PanGenetics and Tanox Inc. in Houston, he held the position of VP Preclinical in which he was world-wide responsible for preclinical safety assessments and animals studies for the Tanox group. Thereafter Louis was one of the founders of MacroZyme BV and for 2 years Director of Preclinical R&D of MacroZyme BV. Besides founder of Bioceros he held a position as CSO for 4AZA Bioscience NV and VP Preclinical (ad interim) for PanGenetics BV until the end of 2006. He has extensive experience in molecular and cellular immunology and in therapeutic antibody development and has been involved in the trajectory of preclinical preparation and design of First into Man studies using therapeutic antibodies. He is also (co)-author of over 250 papers in international scientific journals in the field of medical biotechnology.

Louis holds a Ph.D. in Biochemistry at the University of Amsterdam.

REMCO BRANDT

COO, Managing Director

Remco Brandt held several scientific and management positions over the last decades in both academic institutions and biotech companies in the Netherlands, Germany and the US. Lastly he was one of the founders of MacroZyme BV and for 2 years Director of Operations of MacroZyme BV and CEO of Cilian GmbH from 2005 until 2011. He was closely involved in the establishment of several new life science laboratories and biotech companies. He has a broad experience in operations, administration, HR and finance specifically for biotech-oriented organizations. Besides founder of Bioceros, he is also founder/managing director of Life Science Purchasing Power BV, BiocerOX Products, Ambracia Biopharmaceuticals and Cluster40 Therapeutics. Furthermore, Remco is CEO of Aristi Biotech and Cluster270 Therapeutics, both companies within the Polpharma Group. He is also (co)-author of over 30 peer-reviewed scientific articles.

Remco holds a Master of Science degree in Management. For more details: www.linkedin.com/in/remcombrandt

EMILE VAN CORVEN

CDO

Prior to joining Bioceros Dr. Emile van Corven was a principal consultant CMC at Xendo. From 2001-2014 he was employed by Crucell/J&J, where he was responsible for the USP and DSP development of MAbs and viral vaccines, and the GMP pilot plant. From 2000-2001 he worked for the Dutch regulatory authorities as head of control lab for the release blood products/vaccines on the European market, and head of a regulatory group for the review of CMC dossiers biological/biotechnological products for access to the European market. Therefor he worked for Pharming, where he held various positions in pharmaceutical development or recombinant proteins and project management. He is also (co)-author of over 30 papers in international scientific journals and is co-inventor on various patents. He was member of accreditation commission to assess the quality of the PDEng program “Bioproduct designer”, Technical University Delft, Netherlands and of the editorial board of “Pharmaceutical Bioprocessing” journal.

Emile holds a Ph.D. in Biochemistry at the Nijmegen University.

Supervisory board

JAN SLOB

Born in 1954 in the Netherlands, he gathered throughout his professional life, which was for a big part spent outside the Netherlands, profound knowledge of the healthcare industry. He occupied various high-ranking positions, in which he showed to be a very good ‘change-manager’, with a clear eye for the strategic business demands without losing touch with the ‘human side’ of the business. Strong team player with the ability to operate in diverse cultural environments.

HANNES TEISSL

Hannes Teissl is a seasoned biopharmaceutical executive with a track record in general management, business turnaround, finance, business development and M&A. Hannes is also a Supervisory Board Member of Polpharma Biologics S.A., a company which he was instrumental in establishing over the last 7 years. Prior to joining Polpharma Biologics, Hannes served 22 years at Sandoz, where he held various international management positions, such as Member of the Global Executive Committee, Global Head of M&A, CEO of Sandoz Germany, Global Head of Biopharmaceuticals, Global Commercial Head of API & Out-Licensing for an Anti-infectives and CEO of Sandoz Germany.

Hannes holds a Master of Economics from the University of Innsbruck.

JÖRG WINDISCH

Dr. Jörg Windisch is the Chief Executive Officer of Polpharma Biologics, a privately-held biotech company which develops its own pipeline of biologics and provides contract development and manufacturing services. He also serves on the Board of Directors of Outlook Therapeutics Inc., a US-based, NASDAQ-traded biotech company.

Before joining Polpharma Biologics, he was the Chief Operating Officer at Affimed NV, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer.

Prior to that, Jörg spent almost 20 years at Novartis, where he most recently served as Chief Scientific Officer for Sandoz Biopharmaceuticals and Global Head Technical Development & Clinical Manufacturing for Novartis Biopharmaceutical Operations. He was instrumental in achieving approval for the first biosimilars in Europe and the US. He was also involved in the development and manufacturing of innovative biologics and in the company’s contract development and manufacturing business.

Jörg holds a PhD in biochemistry and numerous patents in the field of biological medicines.